Objective To investigate the clinical effect of interferon combined with budesonide+ipratropium bromide aero-sol in treating children with viral bronchopneumonia Methods 68 children with asthematoid bronchopneumonia in our hospital from January 2015 to January 2016 were selected and divided into common group and treatment group, 34 cases in each group. Common group was given regular treatment combined with budesonide+ipratropium bromide aerosol. Treatment group was given interferon based on common group. After 1 week treatment, compare the clinical effect, clinic symptom changes, hospital stay and adverse reactions of the two groups. Results (1) Difference of gender, age, weight and BMI of the two groups had no statis-tic significance;(2) Clinical symptoms disappear time and average hospital stay of treatment group were obviously shorter than common group, the difference was statistically significant;(3) After 1 week treatment, total efficiency of treatment group (97.1%) was obviously higher than common group (67.6%);(4) During the treatment, no adverse reactions occurred, and adverse reac-tion rate were similar, the difference was not statistically significant. Conclusion The application of interferon combined with budesonide+ipratropium bromide aerosol in treating children with asthematoid bronchopneumonia can improve clinic symptoms and shorten hospital stay. It has higher clinic effect and no obvious adverse reactions, it can be seen as first therapy for children with asthematoid bronchopneumonia.%目的:研究分析干扰素联合布地奈德+异丙托溴铵雾化吸入治疗小儿病毒性喘息型支气管肺炎的临床效果.方法:选取我院在2015年4月~2016年4月收治的68例小儿病毒性喘息型支气管肺炎患者,随机分成常规组与对照组,每组各34例.常规组患儿予病毒性喘息型支气管肺炎常规治疗上加用布地奈德+异丙托溴铵雾化吸入,治疗组在常规组基础上联合干扰素治疗,治疗1周后,观察比较2组患者的临床疗效、临床症状的变化、住院天数以及治疗过程中的不良反应.结果:两组患儿在性别、年龄、体重及BMI上差异无统计学意义;治疗组临床症状消失时间及平均住院天数相比较常规组来说,均明显较少;治疗1周后治疗组总有效率(97.1%)明显高于常规组总有效率(67.6%);两组患儿治疗过程中均未出现严重不良反应事件,且不良反应发生率相似,两组比较无统计学意义.结论:临床上使用干扰素联合布地奈德+异丙托溴铵雾化吸入治疗小儿病毒性喘息型支气管肺炎可短时间内明显改善患儿临床症状,缩短患儿住院时间,并有较高的临床疗效且无明显不良反应,可考虑作为临床上治疗小儿病毒性喘息型支气管肺炎的首选治疗方案.
展开▼
